Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO

0
0 / 5 (0 votos)

Journal of the American Pharmacists Association

Fecha de publicación: 1 march 2017

DOI: https://doi.org/10.1016/j.japh.2017.01.004

Autores: Reina Haque, Jiaxiao Shi, Joanie Chung, Xiaoqing Xu, Chantal Avila, Christopher Campbell, Syed A. Ahmed, Lei Chen, Joanne E. Schottinger.

Background: Our objective was to examine the association between adherence to tyrosine kinase inhibitors (TKIs) and molecular monitoring and the risk of disease progression or mortality among patients with chronic phase chronic myeloid leukemia (CML).

Seguir leyendo